Zepbound highlights the importance of understanding the unique properties of each medication, including their active ingredients and weight loss efficacy, to make informed treatment choices for type 2 diabetes and obesity management
12 The impact of these additional five years due to PTA and PTE is profound: Novo Nordisk is projected to earn an estimated $166 billion from Ozempic and Wegovy as a result of this extended period of patent protection, which spans from March 2026 to December 2031
doi: 10.3389/fimmu.2021.799558 158 LambethJ
Saxenda (liraglutide) Saxenda is a GLP-1 medication appropriate for adults who: Have obesity (BMI of 30 or above) Have overweight (BMI of 27 or above) along with a weight-related comorbid condition like high blood pressure, type 2 diabetes, or high cholesterol or triglycerides It is also approved for children ages 12 and above who weigh more than 132 pounds and are considered obese
Some other effects include slowing stomach emptying and reducing appetite
You can also contact us with questions about starting a medical weight loss program at the Aspen Clinic
